ADPKD

You have accessRestricted Access
Kidney Function Reserve Capacity in Early and Later Stage Autosomal Dominant Polycystic Kidney Disease
A. Lianne Messchendorp, Marco van Londen, Jacob M. Taylor, Martin H. de Borst, Gerjan Navis, Niek F. Casteleijn, Carlo A.J.M. Gaillard, Stephan J.L. Bakker, Ron T. Gansevoort and on behalf of the DIPAK Consortium

CJASN November 2018, 13 (11) 1680-1692; DOI: https://doi.org/10.2215/CJN.03650318

Add to Selected Citations
You have accessRestricted Access
Recent Advances in the Management of Autosomal Dominant Polycystic Kidney Disease
Fouad T. Chebib and Vicente E. Torres

CJASN November 2018, 13 (11) 1765-1776; DOI: https://doi.org/10.2215/CJN.03960318

Add to Selected Citations
You have accessRestricted Access
Vascular Dysfunction, Oxidative Stress, and Inflammation in Autosomal Dominant Polycystic Kidney Disease
Kristen L. Nowak, Wei Wang, Heather Farmer-Bailey, Berenice Gitomer, Mikaela Malaczewski, Jelena Klawitter, Anna Jovanovich and Michel Chonchol

CJASN October 2018, 13 (10) 1493-1501; DOI: https://doi.org/10.2215/CJN.05850518

Add to Selected Citations
You have accessRestricted Access
Long-Term Administration of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease
Marie E. Edwards, Fouad T. Chebib, Maria V. Irazabal, Troy G. Ofstie, Lisa A. Bungum, Andrew J. Metzger, Sarah R. Senum, Marie C. Hogan, Ziad M. El-Zoghby, Timothy L. Kline, Peter C. Harris, Frank S. Czerwiec and Vicente E. Torres

CJASN August 2018, 13 (8) 1153-1161; DOI: https://doi.org/10.2215/CJN.01520218

Add to Selected Citations
Open Access
Burden of Proof for Tolvaptan in ADPKD
Reem A. Mustafa and Alan S.L. Yu

CJASN July 2018, 13 (7) 1107-1109; DOI: https://doi.org/10.2215/CJN.00190118

Add to Selected Citations
Open Access
Burden of Proof for Tolvaptan in ADPKD
Reem A. Mustafa and Alan S.L. Yu

CJASN April 2018, CJN.00190118; DOI: https://doi.org/10.2215/CJN.00190118

Add to Selected Citations
You have accessRestricted Access
Fibroblast Growth Factor 23 and Kidney Disease Progression in Autosomal Dominant Polycystic Kidney Disease
Michel Chonchol, Berenice Gitomer, Tamara Isakova, Xuan Cai, Isidro Salusky, Renata Pereira, Kaleab Abebe, Vicente Torres, Theodor I. Steinman, Jared J. Grantham, Arlene B. Chapman, Robert W. Schrier and Myles Wolf

CJASN September 2017, 12 (9) 1461-1469; DOI: https://doi.org/10.2215/CJN.12821216

Add to Selected Citations
You have accessRestricted Access
Effect of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease by CKD Stage: Results from the TEMPO 3:4 Trial
Vicente E. Torres, Eiji Higashihara, Olivier Devuyst, Arlene B. Chapman, Ronald T. Gansevoort, Jared J. Grantham, Ronald D. Perrone, John Ouyang, Jaime D. Blais and Frank S. Czerwiec

CJASN May 2016, 11 (5) 803-811; DOI: https://doi.org/10.2215/CJN.06300615

Add to Selected Citations
You have accessRestricted Access
Automated Segmentation of Kidneys from MR Images in Patients with Autosomal Dominant Polycystic Kidney Disease
Youngwoo Kim, Yinghui Ge, Cheng Tao, Jianbing Zhu, Arlene B. Chapman, Vicente E. Torres, Alan S.L. Yu, Michal Mrug, William M. Bennett, Michael F. Flessner, Doug P. Landsittel, Kyongtae T. Bae and for the Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP)

CJASN April 2016, 11 (4) 576-584; DOI: https://doi.org/10.2215/CJN.08300815

Add to Selected Citations
You have accessRestricted Access
Urinary EGF Receptor Ligand Excretion in Patients with Autosomal Dominant Polycystic Kidney Disease and Response to Tolvaptan
Laura R. Harskamp, Ron T. Gansevoort, Wendy E. Boertien, Wim van Oeveren, Gerwin E. Engels, Harry van Goor and Esther Meijer

CJASN October 2015, 10 (10) 1749-1756; DOI: https://doi.org/10.2215/CJN.09941014

Add to Selected Citations

Main menu

User menu

Search

ADPKD

Pages

About

Author Information

More information